Robert W. Overell, PhD
President and CEO
Dr. Overell is President and CEO of PhaseRx. Prior to founding PhaseRx, he was a General Partner with Frazier Healthcare Ventures, where he participated in raising over $600M of venture capital and invested over $60M in early-stage biotechnology companies. His venture experience spans the spectrum of investment risks and stages, from seed to late stage investing. Dr. Overell was a key figure in the founding and/or growth of several venture-backed companies, including Array Biopharma (NASDAQ:ARRY), and XenoPort (NASDAQ:XNPT). His investments included therapeutics, tools, reagents, instrumentation, bioinformatics and service businesses. Prior to Frazier, Dr. Overell helped found the Immunex gene therapy spinout Targeted Genetics, where he directed the development of novel gene therapy products. At Immunex, he built and led research and development programs in cell and molecular biology, and led development, manufacturing and clinical affairs for the first HIV gene therapy trial in the world, which was approved by the FDA and RAC in 1991.
Dr. Overell was trained as a cell and molecular biologist and has published numerous publications and patents, including a landmark paper on cell transformation in Nature. He obtained his Ph.D. in Biochemistry from the Institute of Cancer Research, University of London, UK, and his B.Sc. in Biological Sciences from the University of Newcastle-upon-Tyne. He has served on numerous corporate boards, including SkeleTech, Array Biopharma (NASDAQ:ARRY), FastTrack, Chimerix (NASDAQ: CMRX), Quantum Dot, Inpharos, Gene Machines, and XenoPort (NASDAQ:XNPT). He also serves on the board and is the immediate past Chairman of YouthCare (www.youthcare.org